tetano
Editor, Senior Moderator
Int J Infect Dis
. 2024 Oct 10:107260.
doi: 10.1016/j.ijid.2024.107260. Online ahead of print. Randomized Immunogenicity Trial Comparing 2019-2020 Recombinant and Egg-Based Influenza Vaccines among Frequently Vaccinated Healthcare Personnel in Israel
Ashley L Fowlkes[SUP] 1 [/SUP], Alon Peretz[SUP] 2 [/SUP], David Greenberg[SUP] 3 [/SUP], Avital Hirsch[SUP] 4 [/SUP], Emily T Martin[SUP] 5 [/SUP], Min Z Levine[SUP] 6 [/SUP], Laura Edwards[SUP] 7 [/SUP], Sarah Radke[SUP] 8 [/SUP], Adam S Lauring[SUP] 5 [/SUP], Jill M Ferdinands[SUP] 6 [/SUP], Chao Zhang[SUP] 6 [/SUP], Young M Yoo[SUP] 6 [/SUP], Jacob Dryer[SUP] 3 [/SUP], Gabriella Newes-Adeyi[SUP] 7 [/SUP], Eduardo Azziz-Baumgartner[SUP] 6 [/SUP], Alicia M Fry[SUP] 6 [/SUP], Arnold S Monto[SUP] 5 [/SUP], Ran Balicer[SUP] 4 [/SUP], Mark G Thompson[SUP] 6 [/SUP], Mark A Katz[SUP] 4 [/SUP]
Affiliations
Background: Trivalent inactivated influenza vaccine effectiveness was low in a prospective cohort of healthcare personnel (HCP) in Israel from 2016-2019. We conducted a randomized immunogenicity trial of quadrivalent recombinant influenza vaccine (RIV4) and standard-dose inactivated influenza vaccine (IIV4) among frequently and infrequently vaccinated previous cohort participants.
Methods: From October 2019 to January 2020, we enrolled and randomly allocated HCP from two Israeli hospitals to receive IIV4 or RIV4. Hemagglutination inhibition (HAI) antibody titers against 2019-2020 vaccine reference influenza viruses were compared between vaccine groups using geometric mean titer (GMT) ratios from sera collected one-month post-vaccination and by frequency of vaccination in the past 5 years (>2 versus ≤2).
Results: Among 415 HCP, the GMT ratio comparing RIV4 to IIV4 was 2.0 (95% confidence interval [CI] 1.7-2.7) for A(H1N1)pdm09, 1.6 (95% CI: 1.3-1.9) for A(H3N2), 1.8 (95% CI: 1.4-2.2) for B(Yamagata), and 1.1 (95% CI: 0.9-1.4) for B(Victoria). Similarly, RIV4 elicited higher HAI titers than IIV4 against all 2019-2020 vaccine reference viruses except B(Victoria) among infrequently and frequently vaccinated HCP (lower bound of GMT ratio 95% CIs ≥1.0).
Conclusions: RIV4 had improved immunogenicity for influenza vaccine strains among both infrequent and frequent vaccinees compared to standard-dose IIV4.
Keywords: Flublok; Influenza vaccine; healthcare personnel; immunogenicity; recombinant.
. 2024 Oct 10:107260.
doi: 10.1016/j.ijid.2024.107260. Online ahead of print. Randomized Immunogenicity Trial Comparing 2019-2020 Recombinant and Egg-Based Influenza Vaccines among Frequently Vaccinated Healthcare Personnel in Israel
Ashley L Fowlkes[SUP] 1 [/SUP], Alon Peretz[SUP] 2 [/SUP], David Greenberg[SUP] 3 [/SUP], Avital Hirsch[SUP] 4 [/SUP], Emily T Martin[SUP] 5 [/SUP], Min Z Levine[SUP] 6 [/SUP], Laura Edwards[SUP] 7 [/SUP], Sarah Radke[SUP] 8 [/SUP], Adam S Lauring[SUP] 5 [/SUP], Jill M Ferdinands[SUP] 6 [/SUP], Chao Zhang[SUP] 6 [/SUP], Young M Yoo[SUP] 6 [/SUP], Jacob Dryer[SUP] 3 [/SUP], Gabriella Newes-Adeyi[SUP] 7 [/SUP], Eduardo Azziz-Baumgartner[SUP] 6 [/SUP], Alicia M Fry[SUP] 6 [/SUP], Arnold S Monto[SUP] 5 [/SUP], Ran Balicer[SUP] 4 [/SUP], Mark G Thompson[SUP] 6 [/SUP], Mark A Katz[SUP] 4 [/SUP]
Affiliations
- PMID: 39395753
- DOI: 10.1016/j.ijid.2024.107260
Background: Trivalent inactivated influenza vaccine effectiveness was low in a prospective cohort of healthcare personnel (HCP) in Israel from 2016-2019. We conducted a randomized immunogenicity trial of quadrivalent recombinant influenza vaccine (RIV4) and standard-dose inactivated influenza vaccine (IIV4) among frequently and infrequently vaccinated previous cohort participants.
Methods: From October 2019 to January 2020, we enrolled and randomly allocated HCP from two Israeli hospitals to receive IIV4 or RIV4. Hemagglutination inhibition (HAI) antibody titers against 2019-2020 vaccine reference influenza viruses were compared between vaccine groups using geometric mean titer (GMT) ratios from sera collected one-month post-vaccination and by frequency of vaccination in the past 5 years (>2 versus ≤2).
Results: Among 415 HCP, the GMT ratio comparing RIV4 to IIV4 was 2.0 (95% confidence interval [CI] 1.7-2.7) for A(H1N1)pdm09, 1.6 (95% CI: 1.3-1.9) for A(H3N2), 1.8 (95% CI: 1.4-2.2) for B(Yamagata), and 1.1 (95% CI: 0.9-1.4) for B(Victoria). Similarly, RIV4 elicited higher HAI titers than IIV4 against all 2019-2020 vaccine reference viruses except B(Victoria) among infrequently and frequently vaccinated HCP (lower bound of GMT ratio 95% CIs ≥1.0).
Conclusions: RIV4 had improved immunogenicity for influenza vaccine strains among both infrequent and frequent vaccinees compared to standard-dose IIV4.
Keywords: Flublok; Influenza vaccine; healthcare personnel; immunogenicity; recombinant.